Merck & Co Cancer Chief Reflects on 'Foundational' Keytruda
Roger Dansey, head of Merck's clinical development in oncology, tells Scrip that the Keynote clinical program for the blockbuster PD-1 inhibitor continues to hit endpoints across diseases and there is much more to come.
You may also be interested in...
Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.